P/E ratio for Titan Pharmaceuticals (TTNP)
P/E ratio as of March 2025 (TTM): -6.26
According to Titan Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.26316. At the end of 2022 the company had a P/E ratio of -20.3.
P/E ratio history for Titan Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -20.3 | -10.62% |
| 2021 | -22.7 | 87.47% |
| 2020 | -12.1 | 208.22% |
| 2019 | -3.92 | -71.78% |
| 2018 | -13.9 | -64.72% |
| 2017 | -39.4 | -112.73% |
| 2016 | 310 | -291.77% |
| 2015 | -161 | -53.94% |
| 2014 | -351 | -466.65% |
| 2013 | 95.6 | -203.83% |
| 2012 | -92.1 | 4.53% |
| 2011 | -88.1 | -63.15% |
| 2010 | -239 | -48.48% |
| 2009 | -464 | |
| 2007 | -82.3 | -48.16% |
| 2006 | -159 | 281.42% |
| 2005 | -41.6 | -46.58% |
| 2004 | -77.9 | 42.16% |
| 2003 | -54.8 | 92.75% |
| 2002 | -28.4 | -90.91% |
| 2001 | -313 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | 17.3 | -376.16% | 🇺🇸 USA |
 | -5.93 | -5.40% | 🇺🇸 USA |
 | -8.20 | 30.99% | 🇺🇸 USA |
 | 11.5 | -283.50% | 🇺🇸 USA |
 | 29.4 | -569.26% | 🇨🇭 Switzerland |
 | 65.9 | -1,152.90% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.